advertisement
Abstract #120317 Published in IGR 25-1
Review: Neuroprotective Nanocarriers in Glaucoma
Pei K; Georgi M; Hill D; Hill D; Lam CFJ; Wei W; Cordeiro MFPharmaceuticals (Basel, Switzerland) 2024; 17:
Glaucoma stands as a primary cause of irreversible blindness globally, characterized by the progressive dysfunction and loss of retinal ganglion cells (RGCs). While current treatments primarily focus on controlling intraocular pressure (IOP), many patients continue to experience vision loss. Therefore, the research focus has shifted to therapeutic targets aimed at preventing or delaying RGC death and optic nerve degeneration to slow or halt disease progression. Traditional ocular drug administration, such as eye drops or oral medications, face significant challenges due to the eye's unique structural and physiological barriers, which limit effective drug delivery. Invasive methods like intravitreal injections can cause side effects such as bleeding, inflammation, and infection, making non-invasive delivery methods with high bioavailability very desirable. Nanotechnology presents a promising approach to addressing these limitations in glaucoma treatment. This review summarizes current approaches involving neuroprotective drugs combined with nanocarriers, and their impact for future use.
UCL Institute of Ophthalmology, London EC1V 9EL, UK.
Full article